BACKGROUND: Nasal polyps are abnormal lesions that cause airway obstruction and can occur along with other respiratory diseases. On account of its association with aspirin exacerbated respiratory disease (AERD), the human discoidin, CUB and LCCL domain containing 2 (DCBLD2) is hypothesized to be a candidate gene for the development of nasal polyps in asthma patients. METHODS: A total of 12 single-nucleotide polymorphisms (SNPs) were genotyped in 467 Korean asthma patients who were stratified further into 108 AERD and 353 aspirin-tolerant asthma (ATA) subgroups. Five major haplotypes were inferred from pairwise comparison of the polymorphisms. The patients were matched to control for confounds, and differences in the frequency distribution of DCBLD2 SNPs and haplotypes were analyzed using logistic models via various modes of genetic inheritance. RESULTS: Results reveal significant association of rs828618 and DCBLD2_ht1 with nasal polyposis in the overall asthma patients group (P = 0.006, P(corr) = 0.05). Interestingly, the strength of association were maintained in the ATA subgroup (P = 0.007, P(corr) = 0.06), and moderate correlation was detected in the AERD subgroup (P = 0.04-0.05, P(corr) > 0.05). CONCLUSIONS: Although further replication and validation are needed, these findings suggest that DCBLD2 could be a potential marker and drug target for treatment of nasal polyposis in Korean asthma patients.
BACKGROUND:Nasal polyps are abnormal lesions that cause airway obstruction and can occur along with other respiratory diseases. On account of its association with aspirin exacerbated respiratory disease (AERD), the human discoidin, CUB and LCCL domain containing 2 (DCBLD2) is hypothesized to be a candidate gene for the development of nasal polyps in asthmapatients. METHODS: A total of 12 single-nucleotide polymorphisms (SNPs) were genotyped in 467 Korean asthmapatients who were stratified further into 108 AERD and 353 aspirin-tolerant asthma (ATA) subgroups. Five major haplotypes were inferred from pairwise comparison of the polymorphisms. The patients were matched to control for confounds, and differences in the frequency distribution of DCBLD2 SNPs and haplotypes were analyzed using logistic models via various modes of genetic inheritance. RESULTS: Results reveal significant association of rs828618 and DCBLD2_ht1 with nasal polyposis in the overall asthmapatients group (P = 0.006, P(corr) = 0.05). Interestingly, the strength of association were maintained in the ATA subgroup (P = 0.007, P(corr) = 0.06), and moderate correlation was detected in the AERD subgroup (P = 0.04-0.05, P(corr) > 0.05). CONCLUSIONS: Although further replication and validation are needed, these findings suggest that DCBLD2 could be a potential marker and drug target for treatment of nasal polyposis in Korean asthmapatients.
Authors: H Nagai; N Sugito; H Matsubara; Y Tatematsu; T Hida; Y Sekido; M Nagino; Y Nimura; T Takahashi; H Osada Journal: Oncogene Date: 2007-01-08 Impact factor: 9.867
Authors: Elizabeth P Smith; Kathleen Shanks; Michael M Lipsky; Louis J DeTolla; Achsah D Keegan; Svetlana P Chapoval Journal: BMC Immunol Date: 2011-05-19 Impact factor: 3.615
Authors: Haizhong Feng; Giselle Y Lopez; Chung Kwon Kim; Angel Alvarez; Christopher G Duncan; Ryo Nishikawa; Motoo Nagane; An-Jey A Su; Philip E Auron; Matthew L Hedberg; Lin Wang; Jeffery J Raizer; John A Kessler; Andrew T Parsa; Wei-Qiang Gao; Sung-Hak Kim; Mutsuko Minata; Ichiro Nakano; Jennifer R Grandis; Roger E McLendon; Darell D Bigner; Hui-Kuan Lin; Frank B Furnari; Webster K Cavenee; Bo Hu; Hai Yan; Shi-Yuan Cheng Journal: J Clin Invest Date: 2014-07-25 Impact factor: 14.808